Free Trial

COSCIENS Biopharma (CSCI) Competitors

COSCIENS Biopharma logo
$3.69 -0.03 (-0.91%)
As of 06/6/2025 03:57 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

CSCI vs. ATRA, PEPG, AVTX, ARTV, IPSC, MRSN, NRXP, VRCA, PMVP, and AKTX

Should you be buying COSCIENS Biopharma stock or one of its competitors? The main competitors of COSCIENS Biopharma include Atara Biotherapeutics (ATRA), PepGen (PEPG), Avalo Therapeutics (AVTX), Artiva Biotherapeutics (ARTV), Century Therapeutics (IPSC), Mersana Therapeutics (MRSN), NRx Pharmaceuticals (NRXP), Verrica Pharmaceuticals (VRCA), PMV Pharmaceuticals (PMVP), and Akari Therapeutics (AKTX). These companies are all part of the "pharmaceutical products" industry.

COSCIENS Biopharma vs.

COSCIENS Biopharma (NASDAQ:CSCI) and Atara Biotherapeutics (NASDAQ:ATRA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, dividends, risk, institutional ownership, community ranking, analyst recommendations and profitability.

Atara Biotherapeutics has a net margin of -132.58% compared to COSCIENS Biopharma's net margin of -428.43%. Atara Biotherapeutics' return on equity of 0.00% beat COSCIENS Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
COSCIENS Biopharma-428.43% -95.93% -45.66%
Atara Biotherapeutics -132.58%N/A -90.16%

In the previous week, Atara Biotherapeutics had 2 more articles in the media than COSCIENS Biopharma. MarketBeat recorded 3 mentions for Atara Biotherapeutics and 1 mentions for COSCIENS Biopharma. COSCIENS Biopharma's average media sentiment score of 1.17 beat Atara Biotherapeutics' score of 0.67 indicating that COSCIENS Biopharma is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
COSCIENS Biopharma
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Atara Biotherapeutics
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Atara Biotherapeutics has a consensus target price of $17.75, indicating a potential upside of 92.31%. Given Atara Biotherapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Atara Biotherapeutics is more favorable than COSCIENS Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
COSCIENS Biopharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Atara Biotherapeutics
1 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.57

Atara Biotherapeutics received 437 more outperform votes than COSCIENS Biopharma when rated by MarketBeat users.

CompanyUnderperformOutperform
COSCIENS BiopharmaN/AN/A
Atara BiotherapeuticsOutperform Votes
437
67.33%
Underperform Votes
212
32.67%

0.7% of COSCIENS Biopharma shares are owned by institutional investors. Comparatively, 70.9% of Atara Biotherapeutics shares are owned by institutional investors. 0.1% of COSCIENS Biopharma shares are owned by company insiders. Comparatively, 4.0% of Atara Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

COSCIENS Biopharma has higher earnings, but lower revenue than Atara Biotherapeutics. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than COSCIENS Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
COSCIENS Biopharma$9.03M1.28-$16.55M-$5.80-0.64
Atara Biotherapeutics$199.73M0.28-$276.13M-$3.72-2.48

COSCIENS Biopharma has a beta of 0.74, meaning that its share price is 26% less volatile than the S&P 500. Comparatively, Atara Biotherapeutics has a beta of 0.19, meaning that its share price is 81% less volatile than the S&P 500.

Summary

Atara Biotherapeutics beats COSCIENS Biopharma on 12 of the 18 factors compared between the two stocks.

Get COSCIENS Biopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for CSCI and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CSCI vs. The Competition

MetricCOSCIENS BiopharmaPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$11.60M$6.70B$5.50B$8.59B
Dividend YieldN/A2.57%5.25%4.17%
P/E Ratio-0.318.5227.1320.04
Price / Sales1.28254.69415.94161.86
Price / CashN/A65.8538.2534.64
Price / Book0.256.596.974.69
Net Income-$16.55M$143.49M$3.23B$247.88M
7 Day Performance6.22%7.55%7.72%4.14%
1 Month Performance4.12%12.82%14.18%11.07%
1 Year PerformanceN/A4.99%31.13%13.84%

COSCIENS Biopharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CSCI
COSCIENS Biopharma
N/A$3.69
-0.9%
N/AN/A$11.60M$9.03M-0.3120Gap Down
ATRA
Atara Biotherapeutics
4.2685 of 5 stars
$8.00
+2.6%
$17.75
+121.9%
-35.1%$47.69M$199.73M-0.31330
PEPG
PepGen
2.4373 of 5 stars
$1.44
-1.4%
$7.67
+432.4%
-91.3%$47.12MN/A-0.4830
AVTX
Avalo Therapeutics
2.9766 of 5 stars
$4.35
+8.8%
$30.00
+589.7%
-62.7%$47.10M$441,000.000.0040High Trading Volume
ARTV
Artiva Biotherapeutics
1.6321 of 5 stars
$1.94
+0.5%
$19.40
+900.0%
N/A$47.02M$251,000.000.0081
IPSC
Century Therapeutics
2.666 of 5 stars
$0.54
+2.5%
$4.20
+672.8%
-79.6%$46.83M$114.90M-0.29170High Trading Volume
MRSN
Mersana Therapeutics
3.4356 of 5 stars
$0.37
+8.8%
$5.20
+1,290.7%
-82.6%$46.60M$34.01M-0.61150News Coverage
Analyst Forecast
Short Interest ↑
NRXP
NRx Pharmaceuticals
2.4429 of 5 stars
$2.68
+1.5%
$28.50
+963.4%
-3.8%$46.34MN/A-1.252News Coverage
Analyst Forecast
Gap Up
VRCA
Verrica Pharmaceuticals
3.6344 of 5 stars
$0.54
+9.3%
$8.00
+1,379.6%
-93.0%$45.75M$7.18M-0.3040Gap Down
PMVP
PMV Pharmaceuticals
2.4004 of 5 stars
$0.88
-0.1%
$5.50
+527.1%
-41.2%$45.56MN/A-0.8850
AKTX
Akari Therapeutics
N/A$1.42
+4.8%
N/A-41.3%$45.53MN/A0.009

Related Companies and Tools


This page (NASDAQ:CSCI) was last updated on 6/7/2025 by MarketBeat.com Staff
From Our Partners